Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives

  title={Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives},
  author={Seetha Harilal and Jobin Jose and Della Grace Thomas Parambi and Rajesh Kumar and Githa Elizabeth Mathew and Md. Sahab Uddin and Hoon Kim and Bijo Mathew},
  journal={Journal of Pharmacy and Pharmacology},
Objectives Considerable progress has been made in the treatment of Alzheimer’s disease (AD), but all available strategies focus on alleviating symptoms rather than curing, which means that AD is viewed as an unresolvable neurodegenerative disease. Nanotechnological applications offer an alternative platform for the treatment of neurodegenerative diseases. This review aims to summarize the recent nanomedicine and nanotechnology developments for the treatment of AD. Key findings A plethora of… 
Nanomedicines and phytochemicals targeting Alzheimer’s disease
Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer's Disease.
The present review provides an insight into the pathophysiology of AD and risk factors associated with AD, and the various nanoformulations reported in literature for the diagnosis and treatments of AD have been classified and summarised.
Nanocarriers for Alzheimer’s disease: Research and patent update
An update is provided on various dosage forms based on nanotechnology aimed for AD therapeutics, the patents on nanocarriers for AD and clinical trials on AD drugs.
Nanomedicine: A Promising Way to Manage Alzheimer’s Disease
An overview of how nanotechnology has revolutionized the approaches used to manage AD is provided and the emerging nanomedicines for managing brain diseases like AD could promote the booming growth of research and their clinical availability.
Nanodelivery systems for Alzheimer’s disease: Prospects of natural therapeutic agents
This paper elucidates the use of nanoparticles in managing AD while touching on the prospects of natural therapeutic agents and highlighting future perspectives.
Molecular Insights into Therapeutic Potentials of Hybrid Compounds Targeting Alzheimer’s Disease
The review presents therapeutic promise and potential for the development of many disease-modifying hybrids into next-generation medicines for AD and summarizes the recent progress on synthesis of hybrid compounds, their molecular mechanism, and therapeutic potential.
Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer’s Disease
How chitosan-based NPs could be used to address current challenges in the treatment of AD is reviewed; with a specific focus on the enhancement of blood-brain barrier penetration of anti-Alzheimer drugs and on the reduction of their peripheral side effects.
A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics
The major challenges of brain-drug delivery are highlighted, followed by the role of nanotherapeutics for the diagnosis and treatment of various neurological disorders, and the major role of nanoparticles is highlighted.
Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease.


Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.
The role of nanoparticles in early detection of AD, effective drug targeting to brain and theranostic (diagnosis and therapy) approaches in AD's management are discussed.
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease.
It is demonstrated that these nanocomposites can relieve the AD symptoms by mitigating mitochondrial oxidative stress, suppressing tau hyperphosphorylation, and preventing neuronal death both in vitro and in vivo.
Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease
The results suggest that curcumin encapsulated-PLGA nanoparticles are able to destroy amyloid aggregates, exhibit anti-oxidative property and are non-cytotoxic.
Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease.
Recent progress in AChEI, challenges in their effective brain delivery (physicochemical properties and biological barriers) and possible nanotechnology-based strategies that can deliver drugs across the CNS barriers during AD are highlighted.
The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease.
Guidance of Magnetic Nanocontainers for Treating Alzheimer's Disease Using an Electromagnetic, Targeted Drug-Delivery Actuator.
A novel nanotechnology-based strategy to deliver therapeutic agents to the brain via the BBB as a possible therapeutic approach for AD and an effective strategy for regulating the biodistribution of MNPs in the brain through the application of an external electromagnetic field are developed.
Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease.
Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice.
Resveratrol and Grape Extract-loaded Solid Lipid Nanoparticles for the Treatment of Alzheimer’s Disease
Evidence is provided that grape skin and grape seed extracts increase the inhibition effect on Aβ aggregation, and solid lipid nanoparticles functionalized with an antibody, the anti-transferrin receptor monoclonal antibody (OX26 mAb), can work as a possible carrier to transport the extract to target the brain.
Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer’s disease models
Investigation of the potential protective effect of indomethacin-loaded lipid-core nanocapsules (IndOH-LNCs) against cell damage and neuroinflammation induced by amyloid beta (Aβ)1-42 in AD models shows that IndOH- LNCs attenuated Aβ-induced cell death and were able to block the neuro inflammation triggered by Aβ1- 42 in organotypic hippocampal cultures.